Deficiency in energy metabolisms is perhaps the earliest modifiable defect in brain aging and sporadic Alzheimer's disease (sAD). Several high-energy compounds (HECs) such as ATP, phosphoenolpyruvate, phosphocreatine and acetyl coenzyme A have been shown to exhibit neuroprotective effects. To understand their mechanism of actions, we tested the effects of these HECs on intracellular Ca(2+), a central regulator in brain function. Our data showed that the HECs robustly and dose-dependently mobilized intracellular Ca(2+) in cultured SH-SY5Y cells, and the actions were sensitive to intracellular Ca(2+) chelator BAPTA-AM or energy metabolism blocker rotenone. The Ca(2+) influx triggered by the HECs was from both extracellular medium and intracellular stores and the HECs also induced repetitive Ca(2+) oscillations. As these actions were similar to those of classical Ca(2+) agonists, the HECs may be viewed as a new group of physiological Ca(2+) agonists. We also found that the HECs promoted the intracellular activity of calpain, a Ca(2+)-dependent protease, and the enzyme activity fluctuated in concert with cellular energy levels, suggesting that calpain activity may also be energy-driven or energy-dependent. These findings may add to current knowledge for the regulatory mechanisms of Ca(2+) and calpain. Since Ca(2+) and calpain undergo critical dysfunction in brain aging but the underlying mechanisms remain elusive, our work may provide a new perspective for clarifying some controversies. More importantly, the HECs, as key intermediates in glucose catabolism, the primary source of energy supply in the brain, may be used as potential drugs for rational prevention of sAD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.brainresbull.2014.01.006 | DOI Listing |
Eur J Neurol
January 2025
Department of Pharmacotherapy, University of Utah Health, Salt Lake City, Utah, USA.
Background: Reduction of intracellular Na accumulation through late Na current inhibition has been recognized as a target for cardiac Ca handling which underlies myocardial contractility and relaxation in heart failure (HF). Riluzole, an Na channel blocker with enhancement of Ca-activated K channel function, used for management of amyotrophic lateral sclerosis (ALS), is effective in suppressing Ca leak and therefore may improve cardiac function.
Objectives: The study aim was to investigate whether riluzole lowers HF incidence.
Alzheimers Dement
December 2024
Volgograd State Medical University, Volgograd, Russian Federation.
Background: Closely related to the subfamily of proapoptotic proteins is the antiapoptotic protein bcl-2, which acts as an intracellular blocker of the mitochondrial apoptotic pathway. By inhibiting the action of effector caspases, as well as blocking the release of AIF and cytochrome C, Bcl-2 prevents regulated cell death and ensures survival in conditions of damage.
Method: The study was performed on Wistar rats, which were subjected to gravitational overloads (9g) in the caudocranial vector for 5 minutes twice a day for 28 days.
Alzheimers Dement
December 2024
Department of Psychiatry, University of Cambridge, Cambridge, UK.
Background: Combinations of blood-based biomarkers have been used to detect Alzheimer's disease (AD). While these markers provide information about neuropathology, they fail to integrate the cellular dysfunction, such as disease-associated defects in lysosomal ion homeostasis. To understand cellular dysfunction in AD and its relation to the pathophysiology of the disease, we developed a multi-modal biomarker diagnostic platform that incorporates lysosomal ionic pH and Ca and plasma levels of Amyloid beta (Aβ), Amyloid beta (Aβ), phosphorylated Tau181 (pTau181), Neurofilament light (NfL) and Glial fibrillary acidic protein (GFAP).
View Article and Find Full Text PDFBackground: While the formation of β-amyloid plaques and neurofibrillary "tau" tangles are considered hallmarks of AD pathology, therapeutic targeting of these pathways has been unsuccessful, highlighting the necessity to define the underlying molecular mechanisms driving AD progression. Previous studies from our lab demonstrated that mitochondrial calcium (Ca) overload through neuronal ablation of the mitochondrial Na/Ca exchanger (NCLX) is sufficient to trigger 'AD-like' pathology, including mitochondrial dysfunction, amyloid deposition and tau pathology, and cognitive decline. In addition, we found significant proteomic remodeling of components of the mitochondrial calcium uniporter channel (mtCU), the primary mediator of Ca uptake, in frontal cortex samples isolated post-mortem from patients diagnosed with non-familial/sporadic AD.
View Article and Find Full Text PDFBackground: CHRFAM7A is a human-restricted gene associated with neuropsychiatric and neurodegenerative disorders. The translated CHRFAM7A protein incorporates into the α7 nicotinic acetylcholine receptor (α7nAChR) leading to a hypomorphic receptor. Mechanistic insight from isogenic iPSC derived neuronal and mononuclear cells demonstrated that CHRFAM7A affects Ca signaling and activates small GTPase Rac1 leading to an actin cytoskeleton gain of function.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!